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The National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group (WG) on August 5 to 6, 2010
in Bethesda, Maryland to discuss future directions of research in heart transplantation (HT). The WG was com-
posed of researchers with expertise in the basic science, clinical science, and epidemiological aspects of ad-
vanced heart failure and HT. These experts were asked to identify the highest priority research gaps in the field
and make recommendations for future research strategies. The WG was also asked to include approaches that
capitalize on current scientific opportunities and focus on areas that required unique NHLBI leadership. Finally,
the WG was charged with developing recommendations that would have short- and long-term impact on the field
of HT. The WG participants reviewed key areas in HT and identified the most urgent knowledge gaps. These gaps
were then organized into the following 4 specific research directions: 1) enhanced phenotypic characterization of
the pre-transplant population; 2) donor-recipient optimization strategies; 3) individualized immunosuppression
therapy; and, 4) investigations of immune and non-immune factors affecting late cardiac allograft outcomes.
Finally, because the HT population is relatively small compared with other patient groups, the WG strongly urged
concerted efforts to enroll every transplant recipient into a clinical study and to increase collaborative networks
to optimize research in this field. (J Am Coll Cardiol 2012;59:1263–9) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.050Advances in immunosuppression, along with consensus-
driven clinical care by multidisciplinary teams, have en-
hanced the early survival of patients undergoing heart
transplantation (HT). Despite improvements in early mor-
bidity and mortality, late outcomes at 5 and 10 years still
remain poor for those HT recipients who have successfully
navigated the initial challenges of rejection and infection
(1). Although further optimization of therapeutic strategies
to prevent early rejection remains an important goal, there is
now a critical and growing need to develop a strong evidence-
base that can identify strategies to tailor immunosuppressive
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lopathy, characterize newer forms of rejection, and ultimately,
improve late outcomes in these patients. Recognizing this, the
National Heart, Lung, and Blood Institute (NHLBI) spon-
sored a workshop entitled, “Cardiac Transplantation Research
in the Next Decade: A Goal to Evidence Based Outcomes” in
August 2010. The goals of the workshop were to identify the
highest-priority research gaps in the field of HT and to elicit
recommendations for future research strategies.
There currently exists limited randomized clinical trial evi-
dence for standard management practices in HT beyond the
first year. Scientific evolution in the field of HT remains
dominated by registry-driven multicenter studies, single center
observational studies, and pharmaceutical industry-sponsored
randomized controlled trials (RCTs) focusing on early out-
comes (2–4). Although registry-based publications have
yielded groundbreaking information that has guided therapeu-
tic directions, each of the landmark databases in cardiac
transplantation have significant limitations, including incom-
plete data, lack of adjudication, or a lack of comprehensive
patient enrollment beyond early time points (1,5–7). The field
has also been hampered by a lack of research infrastructure,
such as research networks or consortia, to facilitate multicenter
investigations.
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transplants that occur in the United
States yearly, approximately 2,200,
there are several compelling reasons
for the NHLBI to provide a na-
tional platform for conducting
clinical studies in this field (1).
First, compared with other medi-
cal and device-based therapies,
HT is associated with the most
enduring gain in quality of life and
survival, with a median survival of
10 years (1). There are twice as
many patients listed for HT an-
nually as there are donor hearts
available, and despite parallel ad-
vances in ventricular assist device
therapy, approximately 8% of
these patients die awaiting a suitable allograft (7). In
addition, the candidate pool is evolving and becoming even
more complex with the advent of mechanical circulatory
support, the growing number of adults with congenital heart
disease who have failing hearts with few reparative options,
and the rising population of end-stage heart failure (HF)
patients who require multi-organ transplantation (8). Ad-
ditionally, more than 20% of patients who undergo HT do
not survive beyond 3 years. Of those that do survive beyond
3 years, a population of approximately 20,000 to 40,000
patients, the majority are afflicted with the long-term
complications associated with immunosuppression, such as
metabolic syndrome, chronic kidney disease, coronary allo-
graft vasculopathy, and malignancy (1). This underscores a
need to address both morbidity as well as survival issues in
this large prevalent population of patients. Because HT
patients are meticulously followed, this population is
uniquely poised for enrollment in clinical trials.
The charge to the workshop participants was to focus on
those specific areas in HT that required unique NHLBI
leadership and to develop recommendations that were
visionary, practical, and that would have both short- and
long-term impact on the field. The working group (WG)
identified 4 broad challenges in HT and strongly encour-
aged incorporating basic science investigations into all
clinical studies. Because the HT population is relatively
small, the WG recommended concerted efforts to develop a
research infrastructure that facilitates enrollment of de-novo
and existing HT recipients into clinical trials to optimize
research within the field. Although the National Institute of
Allergy and Infectious Diseases has successfully supported
HT research as part of 2 consortiums addressing transplan-
tation research in all organs, entitled Clinical Trials in
Organ Transplantation and Clinical Trials in Organ Trans-
plantation in Children, there is a need for a complementary
but more specialized HT network that could potentially
facilitate multiple trials and studies focused on cardiac
Abbreviations
and Acronyms
AMR  antibody mediated
rejection
CAV  cardiac allograft
vasculopathy
CNI  calcineurin inhibitor
HF  heart failure
HT  heart transplantation
LVAD  left ventricular
assist device
NHLBI  National Heart,
Lung, and Blood Institute
RCT  randomized
controlled trial
WG  working groupissues. The 4 broad key challenges and corresponding recom-mendations identified by the WG are listed in Table 1 and
discussed in the following text.
Challenge #1: Optimize and
Individualize Immunosuppression
Therapies and Improve Late Allograft Outcomes
Mediated by Immune and Non-Immune Factors
Greater efforts should be focused on developing optimal
practices that individualize immunosuppression therapies
and manage the long-term effects of these drugs. In addi-
tion, research strategies need to address the non-immune
complications of immunosuppression, such as diabetes mel-
litus, hypertension, obesity, the metabolic syndrome,
chronic kidney disease, and malignancies.
Recommendations. A key research priority should be to
develop clinical trials that evaluate how calcineurin inhibitor
(CNI) sparing and elimination approaches, coupled with
intensive strategies aimed at modifying non-immune risk
markers, affect late outcomes. Pharmacogenomic, systems
biology, and other basic science investigations into the
responses of the individual to immunosuppression should be
incorporated into these trials. Fundamental research aimed
at elucidating potential biomarkers that might help diagnose
and predict acute and chronic rejection could play a critical
role in advancing the clinical care of HT patients.
Discussion. Late outcomes in the HT population remain
poor with a median cardiac allograft survival of 11 years, a
statistic that has not improved in over a decade (1). The
major causes of late morbidity and mortality are chronic
kidney disease, cardiac allograft vasculopathy (CAV), and
malignancy (1).
Immediately after transplant, immunosuppression ther-
apy typically consists of a CNI, cyclosporine or tacrolimus,
a purine synthesis inhibitor such as mycophenolate mofetil,
and corticosteroids (5). The dosing of these drugs, which
have a narrow therapeutic index, is typically based on the
weight and renal function of a patient (5). Although other
factors might play a significant role in the dosing and
selection of immunosuppressive drugs, individual character-
istics such age, sex, race, and antibody status are not
currently taken into account routinely (5). In addition,
during follow-up, there are no algorithms that incorporate
individual characteristics into a standard assessment for
tailoring immunosuppression. Because the primary focus in
these patients is preventing rejection, many recipients re-
ceive higher doses of these drugs than might be needed.
This higher exposure might contribute to complications of
obesity, chronic kidney disease, hypertension, and hypergly-
cemia. Strategies aimed at individualizing immunosuppres-
sion should minimize adverse events, preserve immunologic
outcomes, and have a beneficial impact on late outcomes.
To address this broad challenge, the WG recommended
pursuing trials that addressed 2 specific issues—evaluating
an early CNI sparing approach and investigating the impact
of intensive risk marker modification on early and late
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solid cancers, renal failure, and graft and patient survival.
Because of the synergy of immune and non-immune vari-
ables on morbidity and mortality, the WG urged the
consideration of factorial trial designs that would be able to
address both questions concurrently. The WG also stressed
the importance of planning trials with adequate sample sizes
to ensure the study power necessary to evaluate hard endpoints
such as survival. The WG suggested pursuing adaptive clinical
trial strategies and other study design approaches to maximize
the yield of information. This would be best accomplished by
the development of a cooperative trial network or consortia to
optimize participation.
Potential ideas for trials that were discussed included
testing a CNI-free regimen or early weaning of this class of
drugs. The WG believed that trials evaluating lipid lowering
and blood pressure and glucose control would be relatively
straightforward to implement yet would have the potential
for significant impact on long-term cardiovascular out-
comes. Emerging data suggest that targeting the renin-
angiotensin-aldosterone system after HT has a beneficial
impact on non-immune risk factors and particularly on the
development of CAV (9–11). Possible investigations might
include identifying optimal therapeutic targets for lipid
lowering and blood pressure control, which have not yet
been defined in the HT population. Basic science studies
should be included in these clinical trials to understand
mechanisms of action and develop novel therapeutic targets.
The WG urged pursuing basic studies to investigate how to
prevent early injury and inflammation, induce tolerance,
target the innate immune system, and refine anti-proliferative
therapy.
The WG advised that histological and serological bio-
specimen collection and banking should be an integral part
of all NHLBI sponsored studies, either with well-formulated
prospective hypotheses or to facilitate retrospective ancillary
studies. To address the critical question about how to
personalize and provide a metric for optimal immunosup-
pression, the WG urged using high throughput pharmacog-
enomic technologies and a systems biology approach of
assessing individual responses to these therapies. Again, the
WG urged that focused basic science studies be included in
these approaches to better elucidate mechanisms of cardiac
allograft injury, repair, and fibrosis at a vascular and allograft
level.
Challenge #2: Expansion and Optimization of
the Donor and Recipient Candidate Population
The demand for donor hearts far outstrips the supply, and
novel approaches are needed to expand and optimize both
the donor and recipient population (7). This issue could be
addressed by comparing long-term mechanical support with
HT in specific populations and investigating methods to
standardize how donors are reviewed and used. Currently,
the definition for a “marginal donor” varies considerably bamong institutions, and there is conspicuous reluctance to
use hearts from donors older than 60 years of age. Research
that informs the questions underlying this reluctance might
provide convincing data that ultimately leads to the expan-
sion of the donor pool.
Recommendations. The WG recommended a random-
ized trial comparing the transplantation of hearts from older
donors with the implantation of left ventricular assist
devices (LVADs) as destination therapy in recipients 70
ears of age, in whom there is clinical equipoise about the
ptimal therapy. Basic science investigations addressing
undamental questions about senescence in aged donor
rgans and recipient immune systems should be conducted
n parallel with studies in these populations. Further re-
earch to enhance donor use by exploring novel strategies to
imit development of ischemia-reperfusion injury should
lso be pursued.
iscussion. The WG acknowledged the heterogeneity in
he evaluation of prospective donors and in the definition of
he “marginal” donor organ across centers and organ pro-
urement organizations. Because the criteria used by the
nited Network of Organ Sharing criteria and third-party
ayers to assess the quality of transplant programs are based
argely on 1- and 3-year outcomes, most institutions exer-
ise caution in using donor hearts that might be less than
erfect, citing an inability to assume such risk without
upporting evidence (12). However, single center studies
rom large-volume centers that use donors rejected by many
enters as marginal have demonstrated satisfactory early and
ntermediate outcomes (13–15). Examples of such cases
nclude marginal donors transplanted into older recipients
r into recipients with ongoing comorbidities such as
iabetes mellitus and peripheral vascular disease, which
ould have otherwise precluded the use of donors from the
tandard list.
The WG suggested that one strategy to expand the donor
ool might be to investigate the use of marginal donors in
lderly recipients, a population in whom there is clinical
quipoise about the optimal therapy for end-stage HF.
urrently, the major factors that are taken into account
hen matching donors to recipients are blood type, height,
nd weight (5), but there are no standard guidelines for the
eighting of other relevant factors in decision-making,
esulting in considerable inconsistencies in the types of
onor hearts that are accepted at different institutions. For
xample, in some institutions, donor hearts with slightly
epressed ejection fractions or mild left ventricular hyper-
rophy might be deemed adequate, whereas in other pro-
rams such donor hearts would be discarded. Without clear
vidence about the outcomes associated with different donor
haracteristics informing the donor selection process, it is
robable that many potentially useful organs are currently
eing discarded (16,17). Because an important rate limiting
actor in HT is the number of available donor organs,
tudies that define how to optimize donor use and develop
iomarkers to define organ utility might increase the donor
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those organs deemed to be less than perfect.
The WG also encouraged research to optimize donor
organ use by limiting the ischemia-reperfusion injury that
commonly occurs in donor hearts. Strategies that prevent
prolonged ischemia time or render hearts resistant to injury,
such as hypothermia or the use of agents that mimic
preconditioning or target the mitochondrial permeability
transition pore or other mediators of this innate protective
mechanism, might achieve tissue preservation and maintain
viability for transplantation (18,19).
Challenge #3: Characterize
and Address the Comorbidities
Encountered in the Pre-Transplant Population
The lack of standard clinical approaches creates considerable
variability in treatment assignments in different institutions
and even among cardiologists within the same institution.
The WG participants agreed that continuing advances in
mechanical circulatory support have had a profound impact
on the field of HT and have significantly changed the
candidate population (20–22). The patients currently eval-
uated with advanced HF differ markedly from those seen 10
years ago, but medical therapy and triage decisions are based
only on data derived from earlier populations that did not
receive the benefits of early institution of current HF
therapies to delay disease progression. The WG participants
recognized that there is a critical need for evidence-based
management strategies for many aspects of the clinical
management of the pre-transplant population. However,
they felt it was imperative to address three major clinical
issues—the cardio-renal syndrome, the progression of sec-
ondary pulmonary hypertension, and right ventricular fail-
ure—and called for RCTs evaluating these specific prob-
lems. The WG recommended developing robust clinical
tools to characterize the pre-transplant population and
optimize the timing and selection of candidates for HT
directly, for mechanical circulatory support as a bridge to
transplantation, and for mechanical circulatory support as an
lternative to transplantation for patients with substantial
omorbidity burden or other risks for good post-transplant
urvival.
ecommendations. Clinical trials evaluating management
trategies for renal insufficiency, secondary pulmonary hyper-
ension, and right ventricular failure in the pre-transplant
opulation should be emphasized. Researchers should develop
database that would capture the evolving phenotypes of the
dvanced HF population, define the most current pre-
transplant risk factors, and allow investigators to identify the
most optimal candidates from the limited donor pool.
Discussion. The WG recognized that there were myriad
approaches to handling pulmonary hypertension and the
cardio-renal syndrome in the pre-transplant population
(23–28). To address the optimal management strategy for
pulmonary hypertension, the WG urged pursuing a trialevaluating the impact of a strategy of early LVAD implan-
tation versus chronic inotropic therapy as a primary bridge
to transplantation in patients with end stage HF and
elevated pulmonary artery pressures due to chronic left HF
and pulmonary venous hypertension.
Similarly, the WG group urged pursuing a randomized
trial to evaluate best practices for the cardio-renal syndrome.
The cardio-renal syndrome, a poorly understood process, is
associated with adverse post-transplantation outcomes and
is often exacerbated by the inherent nephrotoxicity of
immunosuppressive drugs (1,5). The WG recommended a
randomized trial to assess outcomes of combined heart-
kidney transplantation versus other renal-sparing strategies
in candidates with diminished renal function.
The WG strongly advised that basic science investiga-
tions and bio-specimen repositories should be embedded
within any randomized trial evaluating these 2 major clinical
challenges. In particular, they felt that it was important to
emphasize the role of renal histology in understanding the
cardio-renal syndrome.
The WG also recognized that increasing the number of
HT that occurs annually depends not only on an enhanced
understanding of the donors but also on a greater knowledge
of the current phenotypes of recipients. At present, there are
no ongoing, complete, adjudicated databases that define the
pre-transplant population adequately to provide a clear
window into the most current clinical issues that afflict this
population. The WG recommended developing a funded
database with a bio-specimen bank that would better define
pre-transplant risk factors—including clinical features, bio-
markers, and genes—that would allow clinicians and inves-
tigators to track the changes in this population as it evolves
and progresses with the advent of novel therapies. The WG
suggested creating a national database, with all transplant
centers enrolling patients listed each year for HT.
Challenge #4: Characterize and
Understand Antibody Mediated Rejection
In the past, the major immunological challenge to survival
in the early post-transplant period was cellular rejection.
However, there is growing recognition that antibody medi-
ated rejection (AMR) might account for significant early
and late morbidity and mortality (29,30). Much progress
needs to be made to better understand AMR at a histolog-
ical, serological, and clinical level. In addition, there are few
evidence-based strategies for the prevention and ameliora-
tion of AMR.
Even though the WG identified AMR as a major research
gap, they also emphasized that AMR and cellular rejection are
different aspects of the process of rejection. The group con-
curred that the overall course of rejection is mediated by both
cellular and soluble antibody factors, acting in concert over
time, with changing roles in the lifetime of a graft, and with
varying contributions in different patients.
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large-scale robust analytical database with a bio-bank to
characterize the pathophysiology and natural history of
AMR. In addition, therapeutic interventions for prevention
and treatment of manifest AMR require study in RCTs.
Discussion. Antibody mediated rejection is now increas-
ingly recognized in the HT population, typically occurs
early, in the setting of sensitization to the allograft, and is
associated with hemodynamic compromise and late devel-
opment of CAV. Recent evidence suggests that even
asymptomatic AMR is associated with a higher risk of CAV
and worse cardiovascular mortality (31,32). The augmented
immunosuppression required during treatment of AMR is
more aggressive and complex than that for cellular rejection
and is associated with a higher incidence of infection and
predisposition to malignancy.
To gain a better understanding of this unique form of
rejection, the WG recommended creating an observa-
tional longitudinal database, which would include a
bio-specimen bank and phenotype information. A bio-
repository that would collect, catalog, and store tissue,
serum, and DNA would be a critically important feature.
Such a database would help investigators characterize the
pathophysiology of AMR, create standardized definitions
of this entity, identify individual risk factors, identify
biomarkers, and ascertain the impact of this form of
rejection on long-term outcomes (33). Importantly, re-
searchers should develop a standardized approach to the
histological definition of AMR and optimal surveillance
strategies for early detection of this entity. In addition,
randomized trials need to be conducted to evaluate the
efficacy of various strategies that attempt to prevent this
form of rejection (34).
High-Priority Knowledge Gaps in Heart Transplantation and PotentiTable 1 High-Priority Knowledge Gaps in Heart Transplantation
Gap in Knowledge Clinical App
● Individualizing Immunosuppression
● Improving Late Outcomes
● RCT of Calcineurin Inhibitor S
Approaches in Immunosuppre
● RCT of Intensive Risk Marker
● Expand and Optimize Donor and Recipient
Candidate Populations
● RCT of Destination LVAD vs. O
Recipients
● Novel Strategies to Limit Isch
● Characterizing and Addressing
Comorbidities Encountered in the Pre-
Transplant Population
● RCT of LVAD vs. Inotropes for
Hypertension Associated with
● RCT of Combined Heart-Kidne
Renal Sparing Strategies
● Database to Capture Evolving
Advanced HF Population
● Characterize and Understand AMR ● Large-Scale Longitudinal Data
Repository
● Therapeutic RCT Based on Em
ScienceAMR  antibody mediated rejection; HF  heart failure; LVAD  left ventricular assist device; RCT  ranClinical Trials in HT
Conducting clinical trials in HT presents unique challenges,
of which perhaps the most daunting is addressing the small
population of HT patients, the majority of whom are taking
multiple concurrent medications and have many comorbidi-
ties. Thus, patient recruitment is a critical rate limiting step.
Some potential solutions might be to form national and
international networks of committed investigators and pro-
actively identify strategies for recruitment and retention as
well as strategies for coordination of sites across North
America and globally. In addition, a crucial step would be to
conduct pilot studies to evaluate the best methods for
screening and recruitment.
To ensure the quality of future clinical trials in HT,
investigators should also proactively address essential issues
of trial conduct such as blinding, crossovers, drop-outs,
surrogate endpoints, and adaptive monitoring designs. Im-
portantly, investigators must address how these elements
must be uniquely modified or interpreted in the context of
the HT population. In addition, investigators should design
rigorous endpoint definitions, efficient data collection
forms, and streamlined and comprehensible informed con-
sent forms that reflect the challenges distinct to HT. To
ensure the highest quality clinical trials, investigators should
also plan to invest time and funding into organizing
standardized oversight committees, such as Data Safety and
Monitoring Boards, Protocol Review Committees, Execu-
tive Committees, Clinical Events Committees, and Publi-
cations Committees. Finally, a critical step to ensure that the
highest quality fundamental and translational science investi-
gations take place within future HT clinical trials will be to
proactively plan basic and mechanistic studies at the beginning
of the trials and ensure that efforts are made to secure funding
search ApproachesPotential Research Approaches
Fundamental Science Approach
or Elimination
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● Pharmacogenomics, Systems Biology, and Other
Basic Science Approaches to Elucidate:
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Diagnosing Rejection
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as biological markers, DNA banks, and imaging.
Pursuing significant scientific questions is essential to
moving the field of HT forward. However, the WG noted,
an equally important factor to advancing knowledge in this
field will be how well those questions are answered through
rigorous trial design and conduct.
The Role of the NHLBI in Facilitating HT Research
There is a critical need for studies in HT that evaluate
prevention and treatment strategies rather than evaluating
the efficacy of single drugs or interventions. In addition,
research in HT needs to expand from focusing on early
outcomes to also addressing late morbidity and mortality.
National Heart, Lung, and Blood Institute and other federal
agency support of such efforts might be particularly impor-
tant, because industry sources are unlikely to independently
fund research in these areas. The WG believed the best way
to address many of the current scientific gaps was through
RCTs, with complementary basic science and mechanistic
investigations embedded in the studies. In addition, the
WG encouraged the NHLBI scientific staff to educate the
HT research community about the opportunities and mech-
anisms for research support that are already available
through the Institute.
Investigators in HT have a critical responsibility to apply
for grants and generate interest and enthusiasm in the
academic medical community for research and enrolling
patients. When developing new research proposals, the
NHLBI encourages investigators to capitalize on novel
scientific opportunities, public-private partnerships, and
attainable short-term goals. There are a number of mecha-
nisms at the NHLBI available to HT investigators inter-
ested in pursuing research support (Table 2). The standard
R01 mechanism can provide up to $499,999 per year in
direct costs for smaller projects in basic or clinical science. In
addition, mechanisms exist for investigator-initiated proj-
ects exceeding $500,000/year. These mechanisms include
grants for large, multi-center clinical trials (R01 or U01) and
program project grants (P01). A complete description of
how to apply for these large grants can be found at the
NHLBI website (35).
Individuals interested in submitting an application cov-
ered by these guidelines are strongly encouraged to begin
informal discussions with NHLBI scientific staff as early as
possible in the process of planning their research proposal.
Selected Grant MechanismsTable 2 Selected Grant Mechanisms
Funding Mechanism Title
P01 Program Project Grants Supports c
than a
R01 Regular Research Project Grant Supports a
R34 Clinical Trial Pilot Studies Supports pProposals with budgets exceeding $1.51 million/year requireinvestigators to make a presentation to NHLBI staff and
submit a letter requesting permission to submit a large appli-
cation.
Funding opportunities for clinical trial pilot studies (R34)
are also available at the NHLBI. The purpose of the R34
planning grants is to provide funding for preliminary
studies to obtain data critical to the successful design of
a full-scale clinical trial. An R34 can provide key early
data that might help applicants develop a robust and
competitive investigator-initiated clinical trial (36).
Summary
It is imperative that researchers address the critical scientific
gaps in HT by developing high-quality RCTs and concur-
rent basic science studies that investigate the fundamental
processes of immunology, pharmacogenomics, inflamma-
tion, and repair. Moving the field of HT forward will
depend on an improved understanding of individualized
immunosuppression, a greater knowledge of how to select
and manage donors and recipients, and a strong focus on
improving long-term outcomes by increasing the 10-year
cardiac allograft disease-free survival. Through dedicated
efforts by the research community and the support of the
NHLBI, the goal to develop evidence-based outcomes in
HT over the next decade can evolve from concept to reality.
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